Elixir Medical Corporation  revealed positive 2-year trial results for its DESyne BD coronary stent system at this month’s EuroPCR conference.

The novolimus-eluting DESyne BD stent features an ultra-thin polymer coating that enables sustained drug release and degrades over 6 to 9 months, leaving behind a bare metal cobalt chromium stent.

The long-term results showed that, when compared to Medtronic’s (NYSE:MDT) Endeavor zotarolimus-eluting stent system with durable coating, DESyne BD showed better target lesion revascularization rates. Endpoints and adverse events remained relatively unchanged from 6 months to 2 years.

"The degradable coating technology of DESyne BD has demonstrated a remarkably low MACE rate at 2 years compared with durable polymer platforms," said CEO Motasim Sirhan in prepared remarks. "With the DESyne BD System, Elixir continues to meet physician needs for excellent and sustained clinical outcomes."

The company recently announced an FDA green light to begin the Excella III pivotal trial to review its DESyne Nx for U.S. approval. Elixir won CE Mark approval based on results of the DESolve Nx trial.